Drugs / Haemophilus Influenzae Type b Conjugate Vaccine
Haemophilus Influenzae Type b Conjugate Vaccine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Hexavac | — | 2012-06-28 | europa.eu ↗ |
| Approved | EU (EMA) | Hexavac | — | 2000-10-23 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06621654 Comparator | Nov 2024 → Oct 2026 expected | haemophilus infectious disease | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00322049 Comparator | Feb 2004 → Jun 2009 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Haemophilus influenzae Type b Conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00322049 ↗ |
| Modality | Vaccine | “control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6)” NCT00322049 ↗ |